A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 19, 2017

Primary Completion Date

March 14, 2019

Study Completion Date

December 19, 2019

Conditions
Chronic Kidney Diseases
Interventions
DRUG

COR-001

Anti-inflammatory therapy

DRUG

Placebo

Sterile water with a final buffer of 25 mM Histidine, 8.5% (w/v) trehalose and 0.05% PS80

Trial Locations (1)

80045

University of Coloardo Anschutz Medical Campus, Aurora

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Corvidia Therapeutics

INDUSTRY

lead

University of Colorado, Denver

OTHER